Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Olodaterol Gains Advisory Committee Support, But May See Indication Clarified

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 15-1 that efficacy and safety had been shown, but said the label should not imply it is a treatment for chronic bronchitis and emphysema, just airway obstruction in those conditions, as well as COPD.

Advertisement

Related Content

Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim
Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
BI’s Olodaterol Wants Novel Exercise Claims In COPD
Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel